Resolvyx Pharmaceuticals is developing an entirely new class of medicines called Resolvins. Resolvins are naturally-occurring, small molecule lipid mediators with the potential to treat a wide range of inflammatory diseases. Unlike most anti-inflammatory drugs which suppress the body's inflammatory response, Resolvins work by activating the body's own mechanisms for shutting off, or resolving, inflammation.

Patents 53show all

  • 36
    A61K - Preparations for medical, dental, or toilet purposes
  • 9
    C07C - Acyclic or carbocyclic compounds
  • 2
    A01N - Preservation of bodies of humans or animals or plants or parts thereof

Clinical Trials 2show all

1Phase 11Phase 2

SEC Filings show all


3
D

Contact Information

25 First Street
Cambridge, MA 02141
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$20,700,00011-502010-11-09Operating

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2010-06-18$1,200,000Debt Financing
2005-12-02$17,000,000Series AAtlas Venture, CHL Medical Partners, Flagship Pioneering
2010-11-09$2,500,000Series Unknown

SEC Form D Funding Events

DateOfferedSoldType
2010-11-08$2,500,000$2,500,000Debt, Option to Acquire, Security to be Acquired
2010-06-18$1,200,000$1,200,000Debt, Option to Acquire, Security to be Acquired
2008-08-06Unknown Unknown Other (Paper Filing)

Key Executives

  • Philip J. Vickers
    Executive Officer, Director
  • James Nichols
    Executive Officer
  • Per Gjorstrup
    Executive Officer
  • C. Eric Schwartz
    Executive Officer
  • Timothy J. Barberich
    Director
  • Douglas Cole
    Director
  • Jean-francois Formela
    Director
  • Keith Manchester
    Director
  • George M. Milne, Jr.
    Director
  • Gregory Weinhoff
    Director